We make only minor estimate revisions ahead of Relais' Q4 report, due on 7 March.
NetApp and Dell beat expectations and guide for better growth ahead Storage/server revenues were mai...
Redeye leaves a research update following Klaria Pharma’s Q4 2023 report published earlier today.
Redeye updates its research following Neonode's year-end report.
Redeye updates its estimates following Ngenic’s Q4 report, which presented record net sales but slig...
Resultatet för 2023 landade inom Analysguidens prognos och motiverat värde vid 37,5 kr upprepas.
Redeye returns with an updated view of Saniona following the Q4 report and recent rights issue and r...
Under de senaste åren har Zoomability investerat i verksamheten för att kunna exekvera på Bolagets t...
Tar marknadsandelar i tuffare marknad Adtraction ökade omsättningen med 41,0 procent i det fjärde kv...
EcoRub (”EcoRub” eller ”Bolaget”) levererar unika material där affärsidén är att förädla återvunnen ...
Flowscape dubblade sin omsättningen i kvartalet och nådde ett positivt resultat.
Huddlestock Fintech AS (“Huddlestock” or the “Company”) has demonstrated high growth of 88% througho...
Redeye sees a quarter developing per our expectations, and we make no estimate revisions.
Date of environmental permit announced: 22 April Est.
During 2023 STENOCARE delivered record in gross sales amounting to DKK 6.
Redeye updates its view on Media and Games Invest (MGI) following its Q4 2023 report, showing strong...
Redeye has updated our estimates and fair value range in response to Physitrack’s Q4 2023 report, wh...
Pre-announced Q4 revenues roughly in line, EBIT 6% below We cut estimates on soft FY'24 guidance - c...
The guidance midpoint indicates 10% y/y revenue growth (LSEG Data & Analytics consensus is 6%) for 2...
Cibus' Q4 2023 income from property management (IFPM) was 7% below Infront consensus, adjusted for o...
